# Spark Therapeutics, Inc.

Spark Therapeutics, Inc. is a company headquartered in Philadelphia, PA, United States.

## Company overview

- **Legal name:** Spark Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Philadelphia, PA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001609351

## About

Spark Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001609351, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2019-02-28, it reported annual revenue of USD 64,725,000; net income of USD -78,822,000; total assets of USD 814,352,000 for the fiscal period ended 2018-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2018 (period ended 2018-12-31)

- **Revenue:** $64.7M (USD 64,725,000)
- **Net income:** -$78.8M (USD -78,822,000)
- **Total assets:** $814.4M (USD 814,352,000)
- **Cash and equivalents:** $95.2M (USD 95,247,000)
- **Operating cash flow:** -$70.6M (USD -70,563,000)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $12.1M (USD 12,065,644)
- **Net income:** -$253.5M (USD -253,481,972)
- **Total assets:** $616.8M (USD 616,796,312)
- **Cash and equivalents:** $96.7M (USD 96,748,444)
- **Later filings:** Net income, Total assets, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2016 (period ended 2016-12-31)

- **Revenue:** $20.2M (USD 20,182,835)
- **Net income:** -$123.7M (USD -123,652,527)
- **Total assets:** $373.9M (USD 373,862,795)
- **Cash and equivalents:** $58.9M (USD 58,923,097)
- **Later filings:** Net income, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2015 (period ended 2015-12-31)

- **Revenue:** $22.1M (USD 22,063,674)
- **Net income:** -$47.1M (USD -47,125,778)
- **Total assets:** $329.8M (USD 329,772,514)
- **Cash and equivalents:** $293.5M (USD 293,530,590)

## Recent SEC filings

- Form 8-K — filed 2019-12-17 — period 2019-12-17 — FORM 8-K
- Form 10-Q — filed 2019-11-07 — period 2019-09-30 — 10-Q
- Form 8-K — filed 2019-09-05 — period 2019-09-05 — 8-K
- Form 10-Q — filed 2019-08-08 — period 2019-06-30 — 10-Q
- Form DEF 14A — filed 2019-07-22 — period 2018-12-31 — DEF 14A
- Form 8-K — filed 2019-07-08 — period 2019-07-05 — FORM 8-K
- Form 10-Q — filed 2019-05-10 — period 2019-03-31 — 10-Q
- Form 10-K/A — filed 2019-04-30 — period 2018-12-31 — 10-K/A
- Form 10-K — filed 2019-02-28 — period 2018-12-31 — 10-K
- Form 8-K — filed 2019-02-25 — period 2019-02-22 — FORM 8-K
- Form 8-K — filed 2019-02-19 — period 2019-02-19 — 8-K - EARNINGS RELEASE
- Form 8-K — filed 2019-01-07 — period 2019-01-07 — 8-K JP MORGAN 2019

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/spark-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology